Table 4.
Changes in Anti PLA2R autoantibody titers in individual MN protocol patients from study enrollment (baseline) to 24 months
| Pt # |
Study enrollment(baseline) Anti PLA2R |
3 mos |
6 mos |
9 mos |
12 mos |
18 mos |
24 mos |
Time to clinical remission (best achieved) status (mos) |
|
|---|---|---|---|---|---|---|---|---|---|
| Achieved Partial Remission | Partial remission |
Complete remission |
|||||||
| 1 | 3260 | 621 | 70 | 55.8 | 2.8 | 2.6 | 7.0 | 18 | NA |
| 3 | 730.9 | 46.07 | 3.6 | m | 1.2 | 0.86 | 0.97 | 6 | NA |
| 5 | Negative* | - | - | - | - | - | 142 | 3 | NA |
| 6 | 295.6 | 5.4 | 19 | 7.3 | 23.9 | 1.7 | 0.6 | 9 | NA |
| 9 | 576.1 | 0.7 | 0.63 | 0.65 | 1.08 | 17.29 | 60.66 | 3 | NA |
| 12 | 78.5 | 1.8 | 2.4 | 2.1 | 1.4 | 1.8 | 1.8 | 3 | NA |
| Achieved Complete Remission | |||||||||
| 2 | 162.7 | 2.4 | 1.45 | 0.7 | 0.8 | 1.5 | 0.8 | 3 | 6 |
| 7 | 260.5 | 0.88 | 1.01 | 0.83 | 0.89 | 0.83 | 1.3 | 3 | 6 |
| 10 | 137.7 | 1.1 | 0.84 | 0.63 | 0.66 | 1.3 | 0.87 | 6 | 9 |
| 13 | 142.6 | 1.4 | 1.5 | 1.5 | 1.5 | 1.08 | 1.1 | 3 | 3 |
| 4 | Negative | - | - | - | - | - | - | 3 | 12 |
| 8 | THSD7A+ | - | - | - | - | - | - | 6 | 9 |
| 11 | Negative | - | - | - | - | - | - | 3 | 12 |
PLA2R antibody titer determined by ELISA; titer > 20 RU/ml is considered seropositive. Subgrouping based on best achieved remission status (partial vs. complete). Nine patients were PLA2R seropositive at baseline by ELISA and one patient (* Pt # 5) had very low levels as detected by Western Blot. During treatment, all seropositive patients became seronegative and achieved remission. This includes subject #8, who was positive for anti-THSD7A at baseline, had negligible levels at 3 mos and undetectable levels by Western Blot for the remaining time points through 24 mos. Yellow shadowing indicates timing of anti PLA2R seronegative status in previously seropositive patients. Brown shadowing indicates return of detectable anti-PLA2R antibody after previously achieving antibody depletion. These patients experienced clinical relapse and were retreated “off protocol”. Pt #6 experienced remission after re-treatment that coincided with anti PLA2R titer becoming negative again. Time to best achieved clinical remission is shown to allow comparisons between timing of immunologic and clinical remission (lag time); m: missing; (−):negative; THSD7A: thrombospondin type-1 domain-containing 7A; NA: not applicable